DIO Valuation

Is A039840 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A039840 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A039840 (₩21850) is trading above our estimate of fair value (₩20818.16)

Significantly Below Fair Value: A039840 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A039840?

Other financial metrics that can be useful for relative valuation.

A039840 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA12.9x
PEG Ratio1.8x

Price to Earnings Ratio vs Peers

How does A039840's PE Ratio compare to its peers?

The above table shows the PE ratio for A039840 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average12.3x
A100120 Vieworks
17.9x26.5%₩263.1b
A206640 Boditech Med
12x20.2%₩310.2b
A041830 InBodyLtd
10.5x13.9%₩386.2b
A043150 Value Added Technology
8.8x17.5%₩457.5b
95.8x53.8%₩317.4b

Price-To-Earnings vs Peers: A039840 is expensive based on its Price-To-Earnings Ratio (95.8x) compared to the peer average (12.3x).


Price to Earnings Ratio vs Industry

How does A039840's PE Ratio compare vs other companies in the KR Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a42.0%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a42.0%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: A039840 is expensive based on its Price-To-Earnings Ratio (95.8x) compared to the KR Medical Equipment industry average (16.6x).


Price to Earnings Ratio vs Fair Ratio

What is A039840's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A039840 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio95.8x
Fair PE Ratio27.3x

Price-To-Earnings vs Fair Ratio: A039840 is expensive based on its Price-To-Earnings Ratio (95.8x) compared to the estimated Fair Price-To-Earnings Ratio (27.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A039840 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩21,850.00
₩36,750.00
+68.2%
4.0%₩39,000.00₩35,000.00n/a4
Mar ’25₩21,100.00
₩36,750.00
+74.2%
4.0%₩39,000.00₩35,000.00n/a4
Feb ’25₩19,380.00
₩38,200.00
+97.1%
8.3%₩44,000.00₩35,000.00n/a5
Jan ’25₩22,400.00
₩38,200.00
+70.5%
8.3%₩44,000.00₩35,000.00n/a5
Dec ’24₩21,100.00
₩38,200.00
+81.0%
8.3%₩44,000.00₩35,000.00n/a5
Nov ’24₩23,600.00
₩42,600.00
+80.5%
6.7%₩47,000.00₩39,000.00n/a5
Oct ’24₩25,300.00
₩43,600.00
+72.3%
5.1%₩47,000.00₩40,000.00n/a5
Sep ’24₩29,950.00
₩43,600.00
+45.6%
5.1%₩47,000.00₩40,000.00n/a5
Aug ’24₩31,200.00
₩43,600.00
+39.7%
5.1%₩47,000.00₩40,000.00n/a5
Jul ’24₩33,950.00
₩43,333.33
+27.6%
6.6%₩47,000.00₩40,000.00n/a3
Jun ’24₩29,000.00
₩38,250.00
+31.9%
23.9%₩47,000.00₩23,000.00n/a4
May ’24₩29,700.00
₩38,250.00
+28.8%
23.9%₩47,000.00₩23,000.00n/a4
Apr ’24₩24,850.00
₩31,250.00
+25.8%
15.7%₩35,000.00₩23,000.00n/a4
Mar ’24₩24,400.00
₩33,000.00
+35.2%
17.0%₩40,000.00₩23,000.00₩21,100.005
Feb ’24₩21,850.00
₩34,500.00
+57.9%
20.1%₩40,000.00₩23,000.00₩19,380.004
Jan ’24₩19,700.00
₩34,500.00
+75.1%
20.1%₩40,000.00₩23,000.00₩22,400.004
Dec ’23₩19,600.00
₩34,500.00
+76.0%
20.1%₩40,000.00₩23,000.00₩21,100.004
Nov ’23₩19,800.00
₩38,333.33
+93.6%
6.1%₩40,000.00₩35,000.00₩23,600.003
Oct ’23₩19,000.00
₩39,750.00
+109.2%
8.0%₩44,000.00₩35,000.00₩25,300.004
Sep ’23₩26,000.00
₩39,750.00
+52.9%
8.0%₩44,000.00₩35,000.00₩29,950.004
Aug ’23₩27,150.00
₩47,333.33
+74.3%
5.3%₩50,000.00₩44,000.00₩31,200.003
Jul ’23₩25,550.00
₩47,333.33
+85.3%
5.3%₩50,000.00₩44,000.00₩33,950.003
Jun ’23₩32,850.00
₩52,600.00
+60.1%
12.8%₩61,000.00₩44,000.00₩29,000.005
May ’23₩34,250.00
₩53,500.00
+56.2%
12.1%₩61,000.00₩44,000.00₩29,700.006
Apr ’23₩35,900.00
₩53,500.00
+49.0%
12.1%₩61,000.00₩44,000.00₩24,850.006
Mar ’23₩32,800.00
₩57,000.00
+73.8%
17.5%₩72,000.00₩44,000.00₩24,400.005

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.